# States Join CMS Medicaid Drug Pricing Pilot

All 50 states, the District of Columbia, and Puerto Rico signed participation agreements for the Centers for Medicare & Medicaid Services’ five-year GENEROUS Medicaid drug-pricing pilot by the September 30 deadline. The pilot links rebates for certain high-cost brand-name drugs to international prices, but expected savings and implementation details remain unclear. Medicaid agencies, health plans, and drug manufacturers may see changes to rebate arrangements as CMS clarifies how the program will operate.

- State Medicaid agencies and health plans should assess how international-price-linked rebates could affect existing drug-pricing and reimbursement arrangements.
- Drug manufacturers with high-cost brand-name products may face changes to Medicaid rebate exposure under the pilot.
- CMS guidance is still needed to clarify implementation requirements and expected savings; stakeholders should use forthcoming details to inform pricing and program planning.

**Jurisdictions:** federal
**Industries:** Healthcare
**Topics:** Regulatory Compliance
**Published:** October 02, 2026

### Government Entities
- Centers for Medicare & Medicaid Services (CMS)
- State Medicaid agencies